Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 389 participants.
Also called NCT04988386
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 389 participants
- Registry
-
NCT04988386 -
2020-005643-22
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Greece, Ireland, Israel, Italy, Netherlands, New Zealand, Portugal, South Korea, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04988386. Allocation not applicable; no masking; primary purpose treatment. Start 2021-10-27 (actual); primary completion 2028-04-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
- Acronym
- AG10
- Condition
- Amyloid Cardiomyopathy, Transthyretin-Related
- Intervention (Drug)
- Acoramidis (AG10)
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
Record details
- Record id
cardio:ct-nct04988386- Content hash
2cd447227c63ac94b2828a5fe9eb27d3fa9f481987c861c753ca07200967f9e9